PharmaSphere: Asia Pacific Deal Trends, 2004–2013

  • September 2013
  • -
  • Global Data
  • -
  • 71 pages

PharmaSphere: Asia Pacific Deal Trends, 2004–2013



Summary



GlobalData’s report, "PharmaSphere: Asia Pacific Deal Trends, 2004–2013" offers an in-depth understanding of the key deals that took place in the region during the last decade. The type of deals covered in the report include Mergers & Acquisitions (M&A), Licensing and Collaboration & Partnerships. The report also provides understanding on the regional differences in the deal making activity to that of the global trends and key trends are outlined with insight on drivers such as regulatory policy, macro-economic and industry factors as well as market access challenges. Case studies including the top deals in value among Mergers & Acquisition, Licensing and Collaboration & Partnerships are strategically analyzed to provide comprehensive understanding on areas such as structure and status of the deal vis a vis the overall corporate strategy.

Throughout the report, GlobalData’s analysts provide you with expert insight, expanding on each strategy and factor discussed, with the aim of providing you with the tools you need to make informed business decisions.

Highlights

About the Report

GlobalData’s report, "PharmaSphere: Asia Pacific Deal Trends, 2004–2013” is an essential source of information and analysis on strategic deals in the Asia Pacific region. It includes top players in the global and regional pharmaceuticals and healthcare market. Using detailed company data and financial analysis, GlobalData has highlighted certain deals in the pharmaceutical market, forming a basis for in-depth analysis of the factors driving deal-making in the industry, currently and into the future. The report discusses the key factors shaping and driving the pharmaceutical industry in the Asia Pacific region, and provides insight on the competitive landscape and emerging strategies that are expected to significantly alter the market position of industry leaders.

Key Questions Answered

- How are the main deal categories faring among top countries in the Asia Pacific region over the past decade?
- What are the primary reasons for increased activity in strategic deals by leading pharmaceutical companies in APAC region?
- What are the key trends, and strategies involved in M&As, licensing deals, and collaboration agreements entered into by leading pharmaceutical and healthcare companies in the Asia Pacific region?
- What strategies are the most successful companies pursuing to gain and maintain their market leading position?



Scope


- In-depth understanding of the key pharmaceutical and healthcare deals that took place in the APAC region during the last decade. Furthermore, key deals are discussed from a domestic and global point of view
- Current regulatory framework in various markets in APAC including recent and/or ongoing developments that are expected to impact or influencing the industry are discussed
- Dealmaking strategies: insightful analysis on the terms, strategic implications and synergies of recent deals activity in the APAC pharmaceutical industry
- Collaboration and acquisition strategies: exhaustive discussion on the strategic implications and synergies of recent M&A and partnering activities
- Expert insights on the corporate strategies of various drug companies seeking a competitive advantage in the pharmaceutical market place
- Case studies on top deal making activities shedding light on rationale and strategy.



Reasons to buy


- Understand the primary drivers behind major deal initiatives in the APAC region.
- Analyze the structures of the deal and gain insight on the various factors considered when structuring deal terms in strategic acquisitions, mergers, collaborations, and licensing.
- Identify rationale behind potential takeover targets and partners, thereby maximizing your opportunities for consolidation, investment, and strategic partnerships in the Asia Pacific region.
- Use this information as an independent source for your due diligence and transaction strategy.

Table Of Contents

Table of Contents

1 Table of Contents 7
1.1 List of Tables 10
1.2 List of Figures 11
2 Introduction 12
2.1 Report Scope 12
2.1.1 Key Questions Answered 12
2.1.2 Key Benefits 13
2.2 Upcoming Related Reports 13
3 Historical Dealmaking Trends 14
3.1 Overview 14
3.2 Leading Deal Drivers 15
3.2.1 Rising Drug Marketing Barriers in Western Developed Economies 15
3.2.2 Generic Competition and the Patent Cliff 15
3.2.3 Move Towards Universal Healthcare Access and Health Insurance Expansion 17
3.2.4 Increasing Consolidation 18
3.3 Overall Deals in Review 19
3.3.1 Review by Deal Type 19
4 Mergers and Acquisitions 23
4.1 Overview 23
4.2 Case Studies 27
4.2.1 Takeda Pharmaceutical Acquires Nycomed 27
4.2.2 Takeda Pharmaceutical Acquires US Firm Millennium Pharmaceuticals 28
4.2.3 Daiichi Pharmaceutical Merges with Sankyo Pharma 29
4.2.4 Yamanouchi Pharmaceutical Merges with Fujisawa Pharmaceutical to Form Astellas Pharma 31
4.2.5 Daiichi Sankyo Acquires India’s Ranbaxy Laboratories 32
4.2.6 Khazanah Nasional Acquires Majority Stake in Parkway Holdings 34
4.2.7 Primary Health Care Acquires Symbion Health 35
4.2.8 Teva Pharmaceutical Industries Acquires Taiyo Pharmaceutical Industry 36
5 Licensing Arrangements 38
5.1 Overview 38
5.2 Case Studies 41
5.2.1 Lundbeck and Otsuka Pharmaceutical Collaborate on Five CNS Drugs 41
5.2.2 Astellas Pharma Enters into Licensing Agreement with AVEO Pharmaceuticals for Tivozanib 42
5.2.3 Takeda Pharmaceutical Enters into Collaboration Agreement with Alnylam Pharmaceuticals 44
5.2.4 Amylin Pharmaceuticals Enters into Licensing Agreement with Takeda Pharmaceutical 45
5.2.5 Janssen Biotech Enters into Licensing Agreement with Astellas Pharma for ASP015K 47
6 Collaborations and Partnerships 49
6.1 Overview 49
6.2 Case Studies 52
6.2.1 Amgen Enters into Co-Development Agreement with Takeda Pharmaceutical 52
6.2.2 Medivation Enters into Co-Development Agreement with Astellas Pharma 54
6.2.3 S*BIO Enters into Co-Development Agreement with Onyx Pharmaceuticals 56
6.2.4 Takeda Pharmaceutical Enters into Agreement with Affymax 58
6.2.5 Ambit Biosciences Corporation Enters into Co-Development Agreement with Astellas Pharma 59
7 Future Outlook 61
7.1 Overview 61
7.2 Deal-Making Trends 61
7.2.1 Licensing Deals to Increase as a Key Source of Pipeline Growth for Big Pharma and Biotech Firms in the APAC Region 61
7.2.2 Acquisitions and Alliances to Expand Geographical Footprint 62
7.2.3 Key Challenges Include Economic Climate, Regulation, Intellectual Property, and Volume-Based Generics Market 63
8 Appendix 65
8.1 Bibliography 65
8.2 Abbreviations 65
8.3 About the Author 68
8.3.1 Aparna Krishnan, Industry Analyst 68
8.4 Director, Healthcare Industry Dynamics 68
8.5 Global Head of Healthcare 69
8.6 About the Industry Dynamics Team 70
8.7 About GlobalData 70
8.8 Disclaimer 70



List of Tables

Table 1: Top-Selling Drugs with Recent and Upcoming US Patent Expirations 16
Table 2: Top 20 MandA Deals by Value, APAC Region, 2004-2013 24
Table 3: Takeda Pharmaceutical Acquires Nycomed 27
Table 4: Takeda Pharmaceutical Acquires Millenium Pharmaceuticals 28
Table 5: Daiichi Pharmaceutical Merges with Sankyo Pharma 29
Table 6: Yamanouchi Pharmaceutical Merges With Fujisawa Pharmaceutical 31
Table 7: Daiichi Sankyo Acquires Ranbaxy Laboratories 32
Table 8: Khazanah Nasional Acquires Majority Stake in Parkway Holdings 34
Table 9: Primary Health Care Acquires Symbion Health 35
Table 10: Teva Pharmaceutical Industries Acquires Taiyo Pharmaceutical Industry 36
Table 11: Top 20 Licensing Deals, APAC Region, 2004-2013 39
Table 12: Lundbeck and Otsuka Pharmaceutical Enter Into Drug Development Collaboration 41
Table 13: Astellas Pharma’s Licensing Deal with AVEO Pharmaceuticals 42
Table 14: Takeda Pharmaceutical Enters into Collaboration Agreement with Alnylam Pharmaceuticals 44
Table 15: Amylin Pharmaceuticals Enters into Licensing Agreement with Takeda Pharmaceutical 45
Table 16: Janssen Biotech Enters into Licensing Agreement with Astellas Pharma 47
Table 17: Top 20 Partnership Deals in the APAC Region, 2004-2013 50
Table 18: Amgen Enters into Co-Development Agreement with Takeda for 13 Drugs 52
Table 19: Medivation Enters into Co-Development Agreement with Astellas Pharma for Prostate Cancer Drug 54
Table 20: S*BIO Enters into Co-Development Agreement with Onyx Pharmaceuticals 56
Table 21: Takeda Pharmaceutical Enters into Agreement with Affymax for Anemia Drug 58
Table 22: Ambit Biosciences Corporation Enters into Co-Development Agreement with Astellas Pharma 59



List of Figures

Figure 1: Number of MandA Deals, APAC Region, 2004-2013 19
Figure 2: Number of Drug Discovery MandA Deals, APAC Region, 2004-2013 20
Figure 3: Number of Licensing Deals, APAC Region, 2004-2013 21
Figure 4: Collaboration and Partnership Deals, APAC Region, 2004-2013 22
Figure 5: Top Five Spenders on MandA Activities ($m), APAC Region, 2004-2013 25
Figure 6: Number of MandA Deals per Country, APAC Region, 2004-2013 26
Figure 7: Upfront and Milestone Payments in the Top 20 Licensing Deals, APAC Region, 2004-2013 40

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

PharmaPoint: Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

PharmaPoint: Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

  • $ 9 995
  • Industry report
  • April 2014
  • by Global Data

PharmaPoint: Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update Summary Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most ...

Pulmonary Drug Delivery Systems: Technologies and Global Markets

Pulmonary Drug Delivery Systems: Technologies and Global Markets

  • $ 6 650
  • Industry report
  • May 2014
  • by BCC Research

Use this report to: - Receive a detailed analysis of the present and future global market for pulmonary drug delivery technologies. - Receive information on pulmonary drug delivery technologies currently ...

Therapeutics for Women%s Health: Technologies and Global Markets

Therapeutics for Women%s Health: Technologies and Global Markets

  • $ 6 650
  • Industry report
  • May 2014
  • by BCC Research

Use this report to: - Learn about the main women's health disorders and relevant disease prevalence population. - Identify the impact of demographic, economic, and other factors that will drive future ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.